Author:
Arriaga Yull,Becerra Carlos R.
Subject
Cancer Research,Pharmacology,Oncology
Reference14 articles.
1. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group (ECOG) study E3200;Giantonio;J Clin Oncol,2005
2. Angiogenesis inhibitors in clinical development; where are we now and where are we going?;Eskens;Br J Cancer,2004
3. Randomized phase II/III trial of paclitaxel plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) trial-4599;Sandler;J Clin Oncol,2005
4. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11;Wildiers;Br J Cancer,2003
5. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer [published erratum in Nat Med 2004; 10:649];Willett;Nat Med,2004
Cited by
16 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献